Cargando…

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

BACKGROUND: Cisplatin is the most commonly used chemotherapeutic agent in the treatment of patients with metastatic and/or recurrent urothelial cancer. However, the effectiveness of these treatments is severely limited due to the development of cisplatin resistance. Cancer stem cells have been docum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagiwara, Masayuki, Kikuchi, Eiji, Tanaka, Nobuyuki, Kosaka, Takeo, Mikami, Shuji, Saya, Hideyuki, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793458/ https://www.ncbi.nlm.nih.gov/pubmed/29385995 http://dx.doi.org/10.1186/s12885-018-3988-3

Ejemplares similares

Sulfasalazine could modulate the CD44v9‐xCT system and enhance cisplatin‐induced cytotoxic effects in metastatic bladder cancer
por: Ogihara, Koichiro, et al.
Publicado: (2019)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023)

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2022)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2021)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma
por: Ide, Hiroki, et al.
Publicado: (2012)

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
por: Murakami, Tetsushi, et al.
Publicado: (2021)

Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer
por: Kobayashi, Hiroaki, et al.
Publicado: (2017)

Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy
por: Hongo, Hiroshi, et al.
Publicado: (2021)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin
por: Ide, Hiroki, et al.
Publicado: (2014)

Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report
por: Umeda, Kota, et al.
Publicado: (2020)

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression
por: Kobayashi, Hiroaki, et al.
Publicado: (2014)

Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer
por: Nishiguchi, Yukiko, et al.
Publicado: (2019)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells
por: Pereira, Carla, et al.
Publicado: (2020)

Response of the Urothelial Carcinoma Cell Lines to Cisplatin
por: Holíčková, Andrea, et al.
Publicado: (2022)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
por: Shojo, Kazunori, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma
por: Li, Cuiyun, et al.
Publicado: (2018)

BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma
por: Gao, Wei, et al.
Publicado: (2017)

Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma
por: Rodrigo, Miguel Angel Merlos, et al.
Publicado: (2021)

TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA
por: Zhang, Shuai, et al.
Publicado: (2022)

Single‐cell RNA‐seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63
por: Tanaka, Nobuyuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ubgck5op84ttbhs42deh08j3h7